Serina Therapeutics, Inc. (SER): debt financing — Serina Therapeutics enters up to $20M convertible note from director Gregory H. Bailey for clinical study SER-252-1b

Serina Therapeutics, Inc.

Up to $20M drawn in 5 tranches tied to milestones for SER-252-1b registrational study; $5M available by Sept 30, 2025.
10% annual interest; conversion at $5.18/share; warrants at $5.44/share for 100% of conversion shares.
Lender is Dr. Gregory H. Bailey, board member and affiliate of largest shareholder Juvenescence; approved by independent special committee.
Senior unsecured; prepayable at any time without penalty; mandatory repayment on change of control or liquidity event.
Maturity 5 years from initial funding; customary events of default with 2% default interest.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Serina Therapeutics, Inc. incurred convertible notes of up to $20 million with Gregory H. Bailey, M.D. at annual rate of 10% maturing five years after the initial funding date.

Instrument: convertible notes
Principal: up to $20 million
Counterparty: Gregory H. Bailey, M.D.
Rate: annual rate of 10%
Maturity: five years after the initial funding date
Event: incurrence

Exact text from the filing

On September 9, 2025, Serina Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an unsecured convertible note (the “Convertible Note”) with Gregory H. Bailey, M.D., a member of the Company’s Board of Directors, making available to the Company an aggregate principal amount of up to $20 million.

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Serina Therapeutics, Inc. issued convertible note to Gregory H. Bailey, M.D. for aggregate principal amount of up to $20 million.

Security: convertible note
Purchaser: Gregory H. Bailey, M.D.
Consideration: aggregate principal amount of up to $20 million

Exact text from the filing

note (the “Convertible Note”) with Gregory H. Bailey, M.D., a member of the Company’s Board of Directors, making available to the Company an aggregate principal amount of up to $20 million. Under the Convertible Note, borrowings may be drawn in the discretion of the Company in five tranches tied to certain clinical and operational milestones, provided that if at

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Serina Therapeutics, Inc. issued 100% of the number of shares issuable upon conversion of the funds extended by the investors on such funding date of warrant to Gregory H. Bailey, M.D. for exercise price equal to $5.44 per share.

Security: warrant
Shares: 100% of the number of shares issuable upon conversion of the funds extended by the investors on such funding date
Purchaser: Gregory H. Bailey, M.D.
Consideration: exercise price equal to $5.44 per share

Exact text from the filing

equal to 100% of the number of shares issuable upon conversion of the funds extended by the investors on such funding date. Such warrants will have an exercise price equal to $5.44 per share. The warrants expire on the earlier of sixty days following the achievement of Milestone 5 or September 30, 2026, unless stockholder approval has not been obtained as

View on SEC.gov

90 debt financings filed in the last 30 days. Browse all debt financings →

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001708599-25-000110

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.